III期临床研究-话题@MedSci

#III期临床研究#

70篇内容 | 2409人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2050151, encodeId=1c36205015145, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, objectType=article, longId=113798, objectId=4275113e9856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4275113e9856, replyNumber=0, likeNumber=72, createdTime=2018-02-22, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4275113e9856, moduleTitle=肾性贫血首创药罗沙司他III期临床研究结果发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4275113e9856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050150, encodeId=1ba7205015096, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, objectType=article, longId=107571, objectId=185210e571e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185210e571e9, replyNumber=0, likeNumber=54, createdTime=2017-11-11, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185210e571e9, moduleTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185210e571e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050148, encodeId=b0b320501489e, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, objectType=article, longId=103410, objectId=211c103410c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=211c103410c6, replyNumber=0, likeNumber=81, createdTime=2018-03-23, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=211c103410c6, moduleTitle=JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=211c103410c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050147, encodeId=3694205014ed3, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, objectType=article, longId=93569, objectId=376693569b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=376693569b4, replyNumber=0, likeNumber=48, createdTime=2017-09-16, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=376693569b4, moduleTitle=J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=376693569b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050143, encodeId=4e272050143f3, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, objectType=article, longId=43449, objectId=ff854344901, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff854344901, replyNumber=0, likeNumber=66, createdTime=2015-10-30, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff854344901, moduleTitle=NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff854344901)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050145, encodeId=fb632050145c1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究, objectType=article, longId=56009, objectId=dfa856009e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa856009e2, replyNumber=0, likeNumber=82, createdTime=2016-06-04, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa856009e2, moduleTitle=招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa856009e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050146, encodeId=c87f2050146e4, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, objectType=article, longId=56019, objectId=a3645601997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3645601997, replyNumber=0, likeNumber=80, createdTime=2015-12-18, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3645601997, moduleTitle=招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3645601997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050144, encodeId=edb0205014405, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效, objectType=article, longId=51623, objectId=b8435162302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8435162302, replyNumber=0, likeNumber=74, createdTime=2016-03-13, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8435162302, moduleTitle=ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8435162302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050142, encodeId=b4bd20501422f, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, objectType=article, longId=38150, objectId=2fcf38150b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fcf38150b2, replyNumber=0, likeNumber=60, createdTime=2015-06-13, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fcf38150b2, moduleTitle=COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fcf38150b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050141, encodeId=c7332050141c3, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=阿斯利康开展司美替尼用于NSCLC的III期临床研究, objectType=article, longId=25791, objectId=ebe925e9168, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebe925e9168, replyNumber=0, likeNumber=77, createdTime=2014-06-01, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebe925e9168, moduleTitle=阿斯利康开展司美替尼用于NSCLC的III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebe925e9168)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050139, encodeId=44ad205013911, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=NEJM：Semagacestat用于老年性痴呆的III期临床研究失败, objectType=article, longId=22118, objectId=4568221184b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4568221184b, replyNumber=0, likeNumber=70, createdTime=2014-04-12, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4568221184b, moduleTitle=NEJM：Semagacestat用于老年性痴呆的III期临床研究失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4568221184b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050140, encodeId=3604205014067, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=昆泰在I、II、III期临床研究市场报告中被誉为**提供商, objectType=article, longId=22899, objectId=7a9e22899e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a9e22899e4, replyNumber=0, likeNumber=0, createdTime=2013-12-07, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a9e22899e4, moduleTitle=昆泰在I、II、III期临床研究市场报告中被誉为**提供商, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a9e22899e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050138, encodeId=907c205013886, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益, objectType=article, longId=10558, objectId=8e311055832, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e311055832, replyNumber=0, likeNumber=105, createdTime=2013-08-20, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e311055832, moduleTitle=Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e311055832)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=慢性淋巴白血病用药GS-1101 开始III期临床研究, objectType=article, longId=5993, objectId=220059936c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=220059936c, replyNumber=0, likeNumber=82, createdTime=2013-02-25, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=220059936c, moduleTitle=慢性淋巴白血病用药GS-1101 开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=220059936c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2050136, encodeId=9d652050136aa, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, objectTitle=farletuzumab治疗卵巢癌将开始III期临床研究, objectType=article, longId=5402, objectId=d871540247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d871540247, replyNumber=0, likeNumber=67, createdTime=2012-08-16, rootId=0, userName=tastas, userId=47c5349, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d871540247, moduleTitle=farletuzumab治疗卵巢癌将开始III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d871540247)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期临床研究

2020-05-29

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

肾性贫血首创药罗沙司他III期临床研究结果发布

2018-02-22

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究

2017-11-11

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

JCO：CD33剪接多态性决定AML患者对吉妥单抗的响应（III期临床研究）

2018-03-23

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

J Gastroenterol：日本人群中Elbasvir 联合grazoprevir 治疗HCV：II/III期临床研究

2017-09-16

zhouqu_8 (审核中...)

前往app查看评论内容

#III期临床研究#

NGGZ：哌加他尼钠针对糖尿病黄斑水肿患者在日本进行III期临床研究

2015-10-30

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

招募患者：索非布韦联合利巴韦林（±干扰素）治疗慢性丙肝的III期临床研究

2016-06-04

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

招募患者：Palbociclib联合来曲唑治疗亚洲女性绝经后晚期乳腺癌的III期临床研究

2015-12-18

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

ASCO 2015：III期临床研究：康复新液对鼻咽癌患者放化疗引起的口腔和上消化道黏膜炎疗效

2016-03-13

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

COPD三联疗法（FF/UMEC/VI)III期临床研究启动（IMPACT试验）

2015-06-13

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

阿斯利康开展司美替尼用于NSCLC的III期临床研究

2014-06-01

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

NEJM：Semagacestat用于老年性痴呆的III期临床研究失败

2014-04-12

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

昆泰在I、II、III期临床研究市场报告中被誉为**提供商

2013-12-07

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

Lancet Oncol：III期临床研究证实晚期鼻咽癌标准治疗方案未使患者获益

2013-08-20

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

慢性淋巴白血病用药GS-1101 开始III期临床研究

2013-02-25

tastas (审核中...)

前往app查看评论内容

#III期临床研究#

farletuzumab治疗卵巢癌将开始III期临床研究

2012-08-16

科室
- - 订阅+
  - 更多科室
工具
服务